title: Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug.
abstract: Maintenance treatment with cisapride was evaluated in 298 patients in whom reflux oesophagitis had been healed with antisecretory drugs. Initially, 34% of the patients had grade-I oesophagitis, 33% had grade II, and 33% had grade III. The patients were treated with 20 mg cisapride twice daily or placebo for 6 months or until endoscopic relapse was shown if this occurred earlier. Survival analysis showed that cisapride significantly prolonged the time to endoscopic relapse in grade-I patients (P = 0.02). The intergroup difference in symptomatic relapse in all patients was also significant (P = 0.010). The effect of cisapride was less clearcut in grade II or III, and/or in patients healed with omeprazole. Factors associated with early relapse were placebo therapy, prior omeprazole therapy, duration of pre-trial symptomatic period, and initial endoscopic severity grade. Adverse experiences were limited; diarrhoea was reported by 9% of the cisapride patients.
authors.affiliation: Dept. of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands.
authors.forename: G N
authors.initials: GN
authors.lastname: Tytgat
authors.forename: O J
authors.initials: OJ
authors.lastname: Anker Hansen
authors.forename: L
authors.initials: L
authors.lastname: Carling
authors.forename: G H
authors.initials: GH
authors.lastname: de Groot
authors.forename: H
authors.initials: H
authors.lastname: Geldof
authors.forename: H
authors.initials: H
authors.lastname: Glise
authors.forename: P
authors.initials: P
authors.lastname: Efskind
authors.forename: L
authors.initials: L
authors.lastname: Elsborg
authors.forename: A L
authors.initials: AL
authors.lastname: Karvonen
authors.forename: B
authors.initials: B
authors.lastname: Ohlin
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D020117:Cisapride; D004311:Double-Blind Method; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use*; D012008:Recurrence; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016019:Survival Analysis
chemical_list: D000897:Anti-Ulcer Agents; D010880:Piperidines; D012702:Serotonin Antagonists; D009853:Omeprazole; D020117:Cisapride